RecruitingPhase 2Phase 3NCT03373968
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Sponsor
Italfarmaco
Enrollment
206 participants
Start Date
Oct 24, 2017
Study Type
INTERVENTIONAL
Conditions
Summary
This is an open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD (Duchenne's muscular dystrophy) patients who have been previously treated in one of the GIVINOSTAT studies.
Eligibility
Sex: MALEMin Age: 7 Years
Inclusion Criteria11
- Must have participated in one of the previous studies with GIVINOSTAT in DMD and have attended the End of Study Visit or must have been screened in study DSC/14/2357/48 and met:
- had a baseline vastus lateralis muscle fat fraction (VL MFF) assessed by MRS in the range ≤5% or \>30%, i.e. included in"off-target" group,
- never been randomized because, the enrollment in the off target group was completed.
- Aged ≥6 years old;
- Are able to give informed assent and/or consent in writing signed by the subject and/or parent/legal guardian (according to localregulations);
- Subjects must be willing to use adequate contraception:
- Contraceptive methods must since the previous GIVINOSTAT study through 3 months after the last dose of study drug, and include the following:
- True abstinence (absence of any sexual intercourse), when in line with the preferred and usual lifestyle of the subject.
- Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
- Condom with spermicide and the female partner must use an acceptable method of contraception, such as an oral,
- transdermal, injectable or implanted steroid-basedcontraceptive, or a diaphragm or a barrier method of contraception in conjunction with spermicidal jelly such asfor example cervical cap with spermicide jelly.
Exclusion Criteria13
- Use of any pharmacologic treatment, other than corticosteroids, that might have had an effect on muscle strength or function within 3 months prior to be enrolled in this study (e.g., growth hormone); Vitamin D, calcium, and any other supplements will be allowed;
- Use of any current investigational drug other than Givinostat;
- Have presence of other clinically significant disease, which, in the Investigator's opinion, could adversely affect the safety of the subject, making it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results;
- Have a diagnosis of other uncontrolled neurological diseases or presence of relevant uncontrolled somatic disorders that are not related to DMD;
- Have platelets count, White Blood Cell and Hemoglobin at screening \< Lower Limit of Normal (LLN)\* (for abnormal screening laboratory test results (\<LLN), the platelets count, White Blood Cell and Hemoglobin will be repeated once; if the repeat test result is still \<LLN, then exclusionary);
- Have Triglycerides \> 300 mg/dL (3.42 mmol/L) in fasting condition at screening visit\* (for abnormal screening laboratory test results (\>300 mg/dL), the triglycerides will be repeated once; if the repeat test result is still \>300 mg/dL, then exclusionary);
- Have inadequate renal function, as defined by serum Cystatin C \>2 x the upper limit of normal (ULN) at screening visit\*. If the value is \>2 x ULN, the serum Cystatin C will be repeated once; if the repeated test result is still \>2 x ULN, the subject should be excluded);
- Have heart failure (New York Heart Association Class III or IV)
- Have a current liver disease or impairment, including but not limited to an elevated total bilirubin\* (i.e. \> 1.5 x ULN), unless secondary to Gilbert disease or pattern consistent with Gilbert's;
- Have a baseline QTcF \>450 msec, (as the mean of 3 consecutive readings 5 minutes apart) or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome);
- Have a psychiatric illness/social situation rendering the potential subject unable to understand and comply with the muscle function tests and/or with the study protocol procedures.
- Have any hypersensitivity to the components of study medication;
- Have a sorbitol intolerance or sorbitol malabsorption or have the hereditary form of fructose intolerance.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGGivinostat
suspension of givinostat (10 mg/mL)
Locations(39)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03373968
Related Trials
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT0728718919 locations
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
NCT0645063925 locations
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
NCT068173829 locations
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
NCT062802098 locations
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT0599600325 locations